Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Torrent Pharmaceuticals Ltd ( (IN:TORNTPHARM) ) has provided an update.
Torrent Pharmaceuticals has deepened its focus on chronic disease therapies, particularly in metabolic and lifestyle-driven conditions, by leveraging its broad international footprint and strong presence in cardiovascular, gastrointestinal and central nervous system drugs. Its extensive manufacturing base and R&D investments position the company to scale complex therapies in both domestic and overseas markets.
The company has launched Semaglutide brands Sembolic and Semalix in India in both oral and injectable forms, entering the fast-growing GLP-1 receptor agonist segment for type-2 diabetes and obesity. Torrent is the first Indian firm to offer generic oral semaglutide and has priced its injectable formulation from Rs 3,999 per month, aiming to expand affordable access and strengthen its position in the competitive metabolic disorders market.
More about Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd. is a specialty-focused Indian drug maker with annual revenues exceeding Rs 11,500 crore and is the flagship company of the Torrent Group, which generates about Rs 45,000 crore in revenue. Following the JB Pharma acquisition, it ranks fifth in the Indian pharmaceuticals market and is among the top five players in cardiovascular, gastrointestinal, central nervous system, pain management and cosmo-dermatology therapies.
About 76% of Torrent Pharma’s India revenue comes from chronic and sub-chronic therapies, underscoring its focus on long-term disease management across key therapeutic areas. The company operates in more than 50 countries and is ranked the leading Indian pharma firm in Brazil and Germany, supported by eight manufacturing facilities, five of which are USFDA-approved, and an R&D workforce of over 750 scientists.
Average Trading Volume: 8,954
Technical Sentiment Signal: Buy
Current Market Cap: 1444.3B INR
For an in-depth examination of TORNTPHARM stock, go to TipRanks’ Overview page.